Patient Journey 1
True or False: Communication breakdowns between referral centers and QTCs can be a common source of delay in CAR-T therapy.
A. True
True or False: Most patients receive clear and comprehensive education about the CAR-T process before consent.
B. False
Through was product did France make her debut in Multiple Myeloma at J&J?
Velcade
How many years combined have the PJLs worked in BioAdvance?
20 years
What is the primary purpose of bridging therapy in CAR-T?
A. Improve quality of life
B. Maintain disease control while waiting for cell manufacturing
C. Reduce toxicity risk
D. Substitute CAR-T therapy
B. Maintain disease control while waiting for cell manufacturing
How long are CAR-T patients typically monitored closely after infusion?
A. 24 hours
B. 1 week
C. 30 days
D. 100 days
C. 30 days
How many sites are currently administering commercial CAR-Ts in Canada today?
13
Which PJL worked in a systemic therapy suite?
Fatima
Which of the following is a key complication after CAR-T infusion are referrers most concerned about?
A. Cytokine Release Syndrome (CRS)
B. Neurologic toxicities
C. Stroke
D. Renal failure
B. Neurologic toxicities
True or False: Data from the CAR-T journey is primarily collected for regulatory reporting, not operational improvement.
True for now but should be for operational improvements as well.
What is the average length of time required to qualify a site?
9-12 months
Which PJL has their Bachelor’s of Nursing?
All
Where do delays most commonly occur in the CAR-T referral process?
A. After patient consent
B. Waiting for Provincial approval
C. During initial referral and eligibility assessment
D. During apheresis scheduling
C. During initial referral and eligibility assessment
Which department is most critical to coordinate closely with the cell processing lab?
A. Emergency Department
B. Infusion Clinic
C. Apheresis Unit
D. Radiology
C. Apheresis Unit
What is normally the rate limiting step to qualify a site?
Contracting
Which PJL has a dog?
Lana
What factor most impacts CAR-T infusion scheduling capacity?
A. Apheresis
B. Bed availability
C. Patient preference
D. Consent turnaround time
B. Bed availability
Which of the following best supports a seamless CAR-T patient journey?
A. Individual decision-making by the Most Responsible Physician (MRP)
B. Frequent handoffs between siloed teams
C. Cross-functional coordination and shared planning
D. More paperwork at each step of the patient journey.
C. Cross-functional coordination and shared planning
When does the CTSL transition Site Operations to the CTOL?
At launch or after the 1st patient
Which PJL has worked at BioAdvance the longest?
Jade